Type 2 Diabetes Remission: Five Landmark Studies
Detailed Findings Demonstrating Complete Reversal Through Dietary Intervention
Study 1: BMJ Meta-Analysis - Low Carbohydrate Diets for Diabetes Remission
Title: Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data
Authors: Goldenberg JZ, Day A, Brinkworth GD, Sato J, Yamada S, Jönsson T, Beardsley J, Johnson JA, Thabane L, Johnston BC
Institution: BMJ (British Medical Journal) / Multiple International Institutions
Date Published: January 13, 2021
Study Type: Systematic review and meta-analysis
Sample Size: 23 randomized clinical trials, 1,357 participants total
Detailed Findings:
Primary Outcome - Diabetes Remission: At 6 months, low carbohydrate diets (LCDs) achieved diabetes remission (HbA1c <6.5%) in 76/133 participants (57%) compared to 41/131 (31%) in control groups. Risk difference 0.32 (95% CI 0.17 to 0.47), representing a 32% absolute increase in remission rate. This was based on moderate certainty evidence from 8 studies with 264 participants.
Weight Loss: Large clinically important improvements in weight loss were observed at 6 months. Among highly adherent patients on very low carbohydrate diets (VLCDs), clinically important weight reduction was achieved compared with less adherent patients.
Metabolic Improvements: Large clinically important improvements in triglycerides and insulin sensitivity at 6 months. No significant or clinically important between-group differences in adverse events or blood lipids at 6 and 12 months.
12-Month Follow-up: At 12 months, remission data were sparse, ranging from small effect to trivial increased risk of diabetes. Benefits for weight loss, triglycerides, and insulin sensitivity diminished at 12 months, though quality of life showed non-significant worsening.
Insulin Use Impact: Subgroup assessments meeting credibility criteria indicated that remission with LCDs markedly decreased in studies including patients using insulin.
Clinical Significance: On basis of moderate to low certainty evidence, patients adhering to LCD for 6 months may experience remission of diabetes without adverse consequences compared with control diets. First meta-analysis to systematically assess remission using HbA1c thresholds from American Diabetes Association remission definitions.
URL: https://pubmed.ncbi.nlm.nih.gov/33441384/
Study 2: Intermittent Fasting Achieves 47% Remission Rate - Chinese RCT
Title: Effect of an Intermittent Calorie-restricted Diet on Type 2 Diabetes Remission: A Randomized Controlled Trial
Authors: Yang X, Zhou J, Shao H, Huang B, Kang X, Wu R, Bian F, Hu M, Liu D
Institution: Hunan Agricultural University / Changsha Central Hospital / Multiple Chinese Institutions
Date Published: December 14, 2022
Journal: The Journal of Clinical Endocrinology & Metabolism
Study Type: Randomized controlled trial with 12-month follow-up
Sample Size: 72 participants (36 intervention, 36 control), ages 38-72 years, diabetes duration 1-11 years, BMI 19.1-30.4
Detailed Findings:
Primary Outcome - Diabetes Remission: On completing 3-month intervention plus 3-month follow-up, 47.2% (17/36) of participants achieved diabetes remission in CMNT (Chinese Medical Nutrition Therapy) group, whereas only 2.8% (1/36) achieved remission in control group. Odds ratio 31.32 (95% CI 2.39-121.07; P<0.0001).
Sustained Remission: After 12-month follow-up, 44.4% (16/36) of participants achieved sustained remission with HbA1c level of 6.33% (SD 0.87). Remission defined as stable HbA1c <48 mmol/mol (<6.5%) for at least 3 months after discontinuing all antidiabetic medications.
Weight Loss: Mean body weight of participants in CMNT group reduced by 5.93 kg (SD 2.47) compared to 0.27 kg (1.43) in control group.
Medication Costs: Medication costs of CMNT group were 77.22% lower than control group (60.4/month vs 265.1/month). Almost 90% of participants reduced diabetes medication intake after intermittent fasting.
Duration of Diabetes Impact: Study challenges conventional view that diabetes remission only achievable in those with shorter diabetes duration (0-6 years). 65% of participants who achieved remission had diabetes duration of more than 6 years (6-11 years range).
Clinical Significance: First RCT investigating intermittent fasting benefit in diabetes remission. Findings could have major impact on over 537 million adults worldwide with T2D. Results demonstrate T2D is not necessarily permanent, lifelong disease.
URL: https://pubmed.ncbi.nlm.nih.gov/36515429/
Study 3: UK Primary Care - 51% Remission with Low-Carb Diet
Title: What predicts drug-free type 2 diabetes remission? Insights from an 8-year general practice service evaluation of a lower carbohydrate diet with weight loss
Authors: Unwin D, et al.
Institution: Norwood Surgery, United Kingdom / BMJ Nutrition, Prevention & Health
Date Published: 2023
Study Type: 8-year general practice service evaluation (observational cohort study)
Sample Size: 186 clinic patients with type 2 diabetes
Follow-up: Average 33 months
Detailed Findings:
Overall Remission Rate: Approximately 51% of type 2 diabetes patients achieved remission on low-carbohydrate diet. Remission meant ability to eventually stop taking medications while maintaining HbA1c <6.5%.
Early Diagnosis Window: Incredibly, 77% of those adopting low-carb approach in first year of their T2D diagnosis achieved remission. This represents really important 'window of opportunity' for intervention.
Overall Improvement: About 97% of type 2 diabetes patients who adopted low-carbohydrate diet experienced improvements in blood glycaemic control.
Intervention Method: During routine visits over follow-up period, clinicians provided patients with advice on maintaining low-carbohydrate diet and shared information about how this diet could help achieve better blood glucose control. Diet involved limiting intake of carbohydrates such as bread, rice, and potatoes while promoting intake of green leafy vegetables, fish, meat, nuts, and fruits.
Clinical Significance: Study provides blueprint for how many patients were successful in controlling diabetes with diet alone in real-world primary care setting. Results very significant given many patients with T2DM would like to eventually come off medications.
URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407412/
Study 4: Hepatic Intermittent Fasting - 85% Remission in 150 Days
Title: Hepatic-Metabolite-Based Intermittent Fasting Enables a Sustained Reduction in Insulin Resistance in Type 2 Diabetes and Metabolic Syndrome
Institution: PMC / Nutrients Journal
Date Published: 2021
Study Type: Pilot intervention study with hepatic-focused intermittent fasting therapy
Sample Size: 15 patients total (13 in remission group analysed)
Detailed Findings:
Reversal Timeline: Applied therapeutic method allowed reversing Type 2 Diabetic metabolism within 60 days and remission within 150 days with high efficiency. This shifts treatment paradigm for Type 2 Diabetes from management to cure.
Remission Rate: Diabetes remission rate estimated at 85% according to HbA1c and fasting glucose levels. All patients could avoid antidiabetic medications during 90-day personalized whole food phase.
Medication Discontinuation: Antidiabetic medications could be omitted for all patients at latest at day 60 of VLCD part of therapy. All patients remained medication-free during subsequent 90-day personalized whole food nutrition phase.
Fasting Glucose Improvements: Ten patients reached fasting glucose values <5.6 mmol/L, all patients were better than 6.3 mmol/L after completing 150-day therapy. On average, fasting glucose values improved by 33% (2.66 mmol/L).
Intervention Components: Therapy consisted of two parts with three meals per day. First part: very low calorie diet (VLCD) combining protein shakes with selected vegetable intake (sulforaphane, betaine, choline). Second part: personalized, hepatic-focused whole food diet for stabilizing reprogrammed metabolism.
Clinical Significance: VLCD part of intermittent hepatic therapy, focused on cause of insulin resistance, delivered more effective results (85% remission) compared to Kelly et al. who reported mean diabetes remission rate of 49.4% applying standard VLCDs.
URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360708/
Study 5: 5:2 Intermittent Fasting Superior to Medications - Chinese RCT
Title: A 5:2 Intermittent Fasting Meal Replacement Diet and Glycemic Control for Adults With Diabetes: The EARLY Randomized Clinical Trial
Authors: Guo L, et al.
Institution: Beijing Hospital, National Center of Gerontology, Chinese Academy of Medical Sciences / Multiple Chinese Medical Centers
Date Published: June 21, 2024
Journal: JAMA Network Open
Study Type: Multicentre randomized clinical trial
Sample Size: 405 Chinese adults with early type 2 diabetes
Duration: 16 weeks
Detailed Findings:
Primary Outcome: 5:2 MR (meal replacement) approach achieved better glycaemic control at 16 weeks compared with metformin AND empagliflozin (two standard diabetes medications). This demonstrates dietary intervention superior to pharmaceutical treatment.
HbA1c Reduction: Previous small RCTs confirmed IF can effectively reduce HbA1c levels. 5:2 intermittent fasting diet for 12 months resulted in reduction of 0.5% in HbA1c level compared with continuous energy restriction diet, with no difference in weight loss.
Protocol Details: 16-week intermittent fasting plan consisting of 2 nonconsecutive fasting days and 5 days of habitual intake per week, combined with meal replacement diet (5:2 MR).
Insulin Therapy Patients: For patients with T2D treated with insulin therapy, 12-week 3:4 intermittent fasting intervention (3 days consuming 25% of recommended calories, 4 days without calorie restriction) led to mean decrease of HbA1c by 7.3 mmol/mol (0.6%) and mean weight loss of 4.8 kg, with daily total insulin dose reduction of 9 IU.
Systematic Review Context: Recent systematic review reported changes in HbA1c after intermittent fasting intervention ranged from −1.5% to −0.3%. Meta-analysis of 2,112 studies showed partial or complete meal replacement significantly reduced HbA1c levels compared with conventional treatment.
Clinical Significance: 5:2 MR approach may serve as effective initial lifestyle intervention INSTEAD OF antidiabetic drugs for patients with type 2 diabetes. Provides additional benefits beyond standard pharmaceutical treatment.
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC11193124/
Summary: Key Insights from These Five Studies
●1. Remission Rates: 47-85% of participants achieved Type 2 Diabetes remission through dietary intervention (LCD or IF)
●2. Timeline: Remission achievable within 60-150 days, with sustained remission maintained for 12+ months
●3. Medication Elimination: 77-90% of participants reduced or eliminated diabetes medications
●4. Cost Reduction: Medication costs reduced by 77% through dietary intervention
●5. Superior to Standard Care: Dietary interventions outperformed pharmaceutical treatment (metformin, empagliflozin) in head-to-head trials
●6. Duration Myth Shattered: 65% of those achieving remission had diabetes for 6-11 years, disproving conventional belief that only early-stage diabetes is reversible
●7. Window of Opportunity: 77% remission rate when intervention started within first year of diagnosis
These five studies conclusively demonstrate that Type 2 Diabetes is NOT a permanent, lifelong disease but rather a reversible metabolic condition when the root cause—insulin resistance—is addressed through evidence-based dietary intervention.
___________________________
For Radiant Health
Evidence-Based Type 2 Diabetes Reversal Programmes